Professor Hellard describes the individual and community benefits of treatment of hepatitis C in people who inject drugs, and calls upon policy makers to ensure that health services are located and structured so that people who inject drugs can access hepatitis C treatment and can be appropriately supported whilst on therapy.
CREIDU has written a submission to United Nations General Assembly Special Session on the World Drug Problem.
This policy brief explores current estimates of syringe coverage in Australia and provides suggestions for improving coverage rates.
The Therapeutic Goods Administration (TGA) is seeking submissions in relation to amending “the scheduling of naloxone to include single use prefilled syringe preparations for injection containing 400 micrograms/mL of naloxone or less in Schedule 3”. Our submission supports amending the scheduling of naloxone from Schedule 4 to Schedule 3.
This brief explores the issue of opioid pharmacotherapy dispensing fees and offers suggestions for resolving this complex issue
Explores the evidence for prison-based programs to reduce injecting drug use and related harm, including post-release overdose.
Explores the risks associated with a return to injecting drug use following release from prison, and highlights prison-based preventative strategies, transitional interventions and the need for more research into health outcomes following release from prison.
A response from the Centre for Research Excellence into Injecting Drug Use (CREIDU) to the proposed Victorian Alcohol and Drug Treatment Principles.
Injecting drug use is a leading risk factor for hepatitis B, however despite this and the availability of a free hepatitis B vaccine, uptake and completion of the full course of hepatitis B vaccination by people who inject drugs (PWID) is low. Professor Maher recommends changes to current policy and practice to promote access to and increase uptake of hepatitis B vaccination for PWID.
Heroin and other opioid overdose is a major cause of death and disability among people who inject drugs. Around one Australian dies from such overdoses every day and there are many more non-fatal overdoses. Naloxone is a cheap, safe and effective overdose-reversal drug. This policy brief advocates for the removal of legislative and practical barriers to the wider distribution of naloxone in Australia.
The link between injecting with unsterile equipment and the spread of HIV, hepatitis C and other blood-borne viruses is well established. Safe injecting facilities (SIFs) provide safer, supervised locations for individuals to inject drugs. This policy brief explores the evidence supporting SIFs, including the positive impact on the individual and on public health and public amenity.